|Bid||2.0000 x 800|
|Ask||2.1000 x 4000|
|Day's Range||1.9500 - 2.1000|
|52 Week Range||0.9570 - 3.3000|
|Beta (5Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
The U.S. FDA has granted Exicure Orphan Drug Designation for its clinical product candidate, cavrotolimod.
Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exicure announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.